Pulmonary Arterial Hypertension Market

DelveInsight’s ‘Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH’s in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. 

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan


Study Period: 2017–2030


Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.


The DelveInsight Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the PAH by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension in the US, Europe and Japan.

Pulmonary Arterial Hypertension Epidemiology

The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.

According to DelveInsight, the total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017. 

Pulmonary Arterial Hypertension Drug Chapters

This segment of the Pulmonary Arterial Hypertension report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The therapeutic market of Pulmonary Arterial Hypertension is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the treatment of Pulmonary Arterial Hypertension. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of PAH. Letairis\Volibris (GlaxoSmithKline plc\Gilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the treatment of Pulmonary Arterial Hypertension. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodeling of blood vessels. 

Pulmonary Arterial Hypertension Market Outlook

The Pulmonary Arterial Hypertension market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, the market of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017, and is expected to increase during the course of the study period (2017–2030). Among the 7MM, the United States accounts for the largest market size of PAH, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Pulmonary Arterial Hypertension Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pulmonary Arterial Hypertension Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Pulmonary Arterial Hypertension Report Key Strengths

• 11 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake 

• Highly Analyzed Market

• Key Cross Competition

Pulmonary Arterial Hypertension Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Pulmonary Arterial Hypertension market

• Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension market

• To understand the future market competition in the Pulmonary Arterial Hypertension market.

1. Key Insights

2. Executive Summary of Pulmonary Arterial Hypertension

3. SWOT Analysis for Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance

4.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017

4.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030

5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification of Pulmonary Arterial Hypertension (PAH)

5.3.1. WHO classification

5.3.2. Functional Classification of PAH

5.4. Etiology

5.5. Risk factors

5.6. Pathophysiology

5.7. Diagnosis

5.7.1. Diagnostic Guidelines: European Guidelines of PAH

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Population and Forecast Parameters

6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

7.1. The United States

7.1.1. Total Prevalent Patient Population of PAH in the United States

7.1.2. Sub-type Specific Prevalence of PAH in the United States

7.1.3. Gender specific Prevalence of PAH in the United States

7.2. Germany

7.2.1. Total Prevalent Patient Population of PAH in Germany

7.2.2. Sub-type Specific Prevalence of PAH in Germany

7.2.3. Gender specific Prevalence of PAH in Germany

7.3. France

7.3.1. Total Prevalent Patient Population of PAH in France

7.3.2. Sub-type Specific Prevalence of PAH in France

7.3.3. Gender specific Prevalence of PAH in France

7.4. Italy

7.4.1. Total Prevalent Patient Population of PAH in Italy

7.4.2. Sub-type Specific Prevalence of PAH in Italy

7.4.3. Gender specific Prevalence of PAH in Italy

7.5. Spain

7.5.1. Total Prevalent Patient Population of PAH in Spain

7.5.2. Sub-type Specific Prevalence of PAH in Spain

7.5.3. Gender specific Prevalence of PAH in Spain

7.6. The United Kingdom

7.6.1. Total Prevalent Patient Population of PAH in the UK

7.6.2. Sub-type Specific Prevalence of PAH in the UK

7.6.3. Gender specific Prevalence of PAH in the United Kingdom

7.7. Japan

7.7.1. Total Prevalent Patient Population of PAH in Japan

7.7.2. Sub-type Specific Prevalence of PAH in Japan

7.7.3. Gender specific Prevalence of PAH in Japan

8. Treatment Algorithm

8.1. Current Treatment Practices

8.2. Treatment Guidelines

8.2.1. CHEST Guidelines [The United States]

8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

9. Unmet Needs

10. Case Studies

10.1. A Rare Case of Drug Induced PAH

10.2. A Case Report of Unconventional Delivery of Inhaled NO

11. Organizations related with PAH

12. Marketed Drugs

12.1. Approval and Market Presence

13. Marketed Drugs by Companies

13.1. United Therapeutics Corporation

13.2. Johnson & Johnson

13.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.

13.4. Bayer AG

13.5. Pfizer

14. Safety and Efficacy of Marketed Drugs

15. Emerging Therapies

15.1. Emerging Drugs Analysis

15.2. Aurora-GT: United Therapeutics

15.2.1. Other Developmental Activities

15.2.2. Clinical Development

15.2.3. Safety and Efficacy

15.3. Ralinepag: United Therapeutics

15.3.1. Other Developmental Activities

15.3.2. Clinical Development

15.3.3. Safety and Efficacy

15.4. Liquidia Technologies

15.4.1. Other Developmental Activities

15.4.2. Clinical Development

15.4.3. Safety and Efficacy

15.5. Bardoxolone Methyl: Reata Pharmaceuticals

15.5.1. Other Developmental Activities

15.5.2. Clinical Development

15.5.3. Safety and Efficacy

15.6. Rodatristat Ethyl: Altavant Sciences

15.6.1. Other Development Activities

15.6.2. Clinical Development

15.6.3. Safety and Efficacy

15.7. Sotatercept: Acceleron Pharma

15.7.1. Other Developmental Activities

15.7.2. Clinical Development

15.7.3. Safety and Efficacy

15.8. PB1064: PhaseBio Pharmaceuticals

15.8.1. Other Developmental Activities

15.8.2. Clinical Development

15.8.3. Safety and Efficacy

15.9. CXA-10: Complexa

15.9.1. Other Developmental Activities

15.9.2. Clinical Development

15.9.3. Safety and Efficacy

16. Other Promising Candidates

16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies

16.1.1. Other Developmental Activities

16.1.2. Clinical Development

16.1.3. Safety and Efficacy

16.2. RT234: Respira Therapeutics

16.2.1. Other Developmental Activities

16.2.2. Clinical Development

16.2.3. Safety and Efficacy

17. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis

17.1. Key Findings

17.2. Total Market Size of PAH in 7MM

17.3. Market Outlook: 7MM

18. United States

18.1. Total Market size of PAH

18.2. PAH Market Size by Therapies

19. EU5 Countries

19.1. Germany

19.1.1. Total Market size of PAH

19.1.2. PAH Market Size by Therapies

19.2. France

19.2.1. Total Market size of PAH

19.2.2. PAH Market Size by Therapies

19.3. Italy

19.3.1. Total Market size of PAH

19.3.2. PAH Market Size by Therapies

19.4. Spain

19.4.1. Total Market size of PAH

19.4.2. PAH Market Size by Therapies

19.5. United Kingdom

19.5.1. Total Market size of PAH

19.5.2. PAH Market Size by Therapies

20. Japan

20.1. Total Market size of PAH

20.2. PAH Market Size by Therapies

21. Market Drivers

22. Market Barriers

23. Appendix

23.1. Bibliography

23.2. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Tables

Table 1: Summary of Pulmonary Arterial Hypertension (PAH) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Pulmonary Arterial Hypertension (PAH)

Table 3: Hemodynamic profiles of pulmonary hypertension

Table 4: Total Prevalent Patient Population of PAH in 7MM (2017–2030)

Table 5: Total Prevalent Population of PAH in the United States (2017–2030)

Table 6: Sub-type Specific Prevalence of PAH in the United States (2017–2030)

Table 7: Gender specific Prevalence of PAH in the United States (2017–2030)

Table 8: Total Prevalent Population of PAH in Germany (2017–2030)

Table 9: Sub-type Specific Prevalence of PAH in Germany (2017–2030)

Table 10: Gender specific Prevalence of PAH in Germany (2017–2030)

Table 11: Total Prevalent Population of PAH in France (2017–2030)

Table 12: Sub-type Specific Prevalence of PAH in France (2017–2030)

Table 13: Gender specific Prevalence of PAH in France (2017–2030)

Table 14: Total Prevalent Population of PAH in Italy (2017–2030)

Table 15: Sub-type Specific Prevalence of PAH in Italy (2017–2030)

Table 16: Gender specific Prevalence of PAH in Italy (2017–2030)

Table 17: Total Prevalent Population of PAH in Spain (2017–2030)

Table 18: Sub-type Specific Prevalence of PAH in Italy (2017–2030)

Table 19: Gender specific Prevalence of PAH in Spain (2017–2030)

Table 20: Total Prevalent Population of PAH in the UK (2017–2030)

Table 21: Sub-type Specific Prevalence of PAH in the UK (2017–2030)

Table 22: Gender specific Prevalence of PAH in the United Kingdom (2017–2030)

Table 23: Total Prevalent Population of PAH in Japan (2017–2030)

Table 24: Sub-type Specific Prevalence of PAH in Japan (2017–2030)

Table 25: Gender specific Prevalence of PAH in Japan (2017–2030)

Table 26: Recommendations for efficacy of drug monotherapy for PAH (group 1) according to WHO functional class.

Table 27: Recommendations for efficacy of initial drug combination therapy for PAH (group 1) according to WHO functional class

Table 28: Recommendations for efficacy of sequential drug combination therapy for PAH (group 1) according to WHO functional class

Table 29: Organizations contributing toward Pulmonary Arterial Hypertension

Table 30: Marketed Drugs for Pulmonary Arterial Hypertension - Approval and Market presence

Table 31: Marketed Drugs developed by United Therapeutics Corporation

Table 32: Marketed Drugs developed by Johnson & Johnson

Table 33: Marketed Drugs developed by GlaxoSmithKline Pharmaceuticals/ Gilead Sciences Inc.

Table 34: Marketed Drugs developed by Bayer (AG)

Table 35: Marketed Drugs developed by Pfizer

Table 36: Safety and Efficacy of Marketed Drugs

Table 37: Aurora-GT, Clinical Trial Description, 2020

Table 38: Ralinepag, Clinical Trial Description, 2020

Table 39: LIQ-861, Clinical Trial Description, 2020

Table 40: Bardoxolone Methyl, Clinical Trial Description, 2020

Table 41: Rodatristat Ethyl, Clinical Trial Description, 2020

Table 42: ACE-011, Clinical Trial Description, 2020

Table 43: PB1064, Clinical Trial Description, 2020

Table 44: PB1064, Clinical Trial Description, 2020

Table 45: iNO, Clinical Trial Description, 2020

Table 46: RT234, Clinical Trial Description, 2020

Table 47: 7 Major Market Size of PAH in USD Million (2017–2030)

Table 48: The US Market size of PAH in USD Million (2017–2030)

Table 49: The US market size of PAH by Therapies in USD Million (2017–2030)

Table 50: Germany Market size of PAH in USD Million (2017–2030)

Table 51: Germany market size of PAH by Therapies in USD Million (2017–2030)

Table 52: France Market size of PAH in USD Million (2017–2030)

Table 53: France market size of PAH by Therapies in USD Million (2017–2030)

Table 54: Italy Market size of PAH in USD Million (2017–2030)

Table 55: Italy market size of PAH by Therapies in USD Million (2017–2030)

Table 56: Spain Market size of PAH in USD Million (2017–2030)

Table 57: Spain market size of PAH by Therapies in USD Million (2017–2030)

Table 58: The UK Market size of PAH in USD Million (2017–2030)

Table 59: The UK market size of PAH by Therapies in USD Million (2017–2030)

Table 60: Japan Market size of PAH in USD Million (2017–2030)

Table 61: Japan market size of PAH by Therapies in USD Million (2017–2030)


List Of Figures:

Figure 1: SWOT Analysis

Figure 2: Some of the common signs & symptoms of Pulmonary Arterial Hypertension (PAH)

Figure 3: Classification of Pulmonary Arterial Hypertension (PAH)

Figure 4: Functional Classification of PAH

Figure 5: Risk Factors of Pulmonary Arterial Hypertension

Figure 6: Pathophysiology of Pulmonary Arterial Hypertension (PAH)

Figure 7: Pathophysiology of Pulmonary Arterial Hypertension (PAH)

Figure 8: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)

Figure 9: ESC/ERS Guidelines for the diagnosis of pulmonary hypertension

Figure 10: Total Prevalent Patient Population of PAH in 7MM (2017–2030)

Figure 11: Prevalence of PAH in the United States (2017–2030)

Figure 12: Sub-type Specific Prevalence of PAH in the United States (2017–2030)

Figure 13: Gender specific Prevalence of PAH in the United States (2017–2030)

Figure 14: Total Prevalent Population of PAH in Germany (2017–2030)

Figure 15: Sub-type Specific Prevalence of PAH in Germany (2017–2030)

Figure 16: Gender specific Prevalence of PAH in Germany (2017–2030)

Figure 17: Total Prevalent Population of PAH in France (2017–2030)

Figure 18: Sub-type Specific Prevalence of PAH in France (2017–2030)

Figure 19: Gender specific Prevalence of PAH in France (2017–2030)

Figure 20: Total Prevalent Population of PAH in Italy (2017–2030)

Figure 21: Sub-type Specific Prevalence of PAH in Italy (2017–2030)

Figure 22: Gender specific Prevalence of PAH in Italy (2017–2030)

Figure 23: Total Prevalent Population of PAH in Spain (2017–2030)

Figure 24: Sub-type Specific Prevalence of PAH in Spain (2017–2030)

Figure 25: Gender specific Prevalence of PAH in Spain (2017–2030)

Figure 26: Total Prevalent Population of PAH in the UK (2017–2030)

Figure 27: Sub-type Specific Prevalence of PAH in the UK (2017–2030)

Figure 28: Gender specific Prevalence of PAH in the United Kingdom (2017–2030)

Figure 29: Total Prevalent Population of PAH in Japan (2017–2030)

Figure 30: Sub-type Specific Prevalence of PAH in Japan (2017–2030)

Figure 31: Gender specific Prevalence of PAH in Japan (2017–2030)

Figure 32: Treatment Options for Pulmonary Arterial Hypertension (PAH)

Figure 33: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)

Figure 34: Unmet Needs of PAH

Figure 35: 7 Major Market Size of PAH in USD Million (2017–2030)

Figure 36: Market Size of PAH in the United States, USD Millions (2017–2030)

Figure 37: The U.S. market size of PAH by therapies in USD Million (2017–2030)

Figure 38: Market Size of PAH in Germany, USD Millions (2017–2030)

Figure 39: Germany market size of PAH by therapies in USD Million (2017–2030)

Figure 40: Market Size of PAH in France, USD Millions (2017–2030)

Figure 41: France market size of PAH by therapies in USD Million (2017–2030)

Figure 42: Market Size of PAH in Italy, USD Millions (2017–2030)

Figure 43: Italy market size of PAH by therapies in USD Million (2017–2030)

Figure 44: Market Size of PAH in Spain, USD Millions (2017–2030)

Figure 45: Spain market size of PAH by therapies in USD Million (2017–2030)

Figure 46: Market Size of PAH in the UK, USD Millions (2017–2030)

Figure 47: The UK market size of PAH by therapies in USD Million (2017–2030)

Figure 48: Market Size of PAH in Japan, USD Millions (2017–2030)

Figure 49: Japan market size of PAH by therapies in USD Million (2017–2030)

Figure 50: Market Drivers

Figure 51: Market Barriers

  • Tags:
  • Pulmonary Arterial Hypertension mar...
  • Pulmonary Arterial Hypertension mar...
  • Pulmonary Arterial Hypertension mar...
  • Pulmonary Arterial Hypertension mar...
  • Pulmonary Arterial Hypertension mar...
  • Pulmonary Arterial Hypertension mar...
  • Pulmonary Arterial Hypertension pip...
  • Pulmonary Arterial Hypertension tre...
  • Pulmonary Arterial Hypertension dru...
  • Pulmonary Arterial Hypertension sal...
  • Pulmonary Arterial Hypertension mar...
  • Pulmonary Arterial Hypertension dis...
  • Pulmonary Arterial Hypertension epi...
  • Pulmonary Arterial Hypertension

Forward to Friend

Need A Quote